Poewe Poewe W W Volc Volc D D Seppi Seppi K K Safety and tolerability of active immunotherapy targeting alpha-synuclein with PD03A in patients with early parkinson’s disease: a randomized, placebo-controlled, phase 1 study Safety and tolerability of active immunotherapy targeting alpha-synuclein with PD03A in patients with early parkinson’s disease: a randomized, placebo-controlled, phase 1 study J Parkinsons Dis J Parkinsons Dis 2021 2021 11 11 1079 1079 1089 1089 supplied-pmid 34092654? Here, SNCA is linked to Parkinson disease.